PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27338064-13 2016 Rosuvastatin treatment reduced the infiltration of inflammatory cells and TNF-alpha and IL-1beta expression. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 74-83 33917884-7 2021 Rosuvastatin/Lactobacillus showed prominent anti-inflammatory effects as revealed by the IL-10/IL-12 ratio and the levels of TNF-alpha and IL-6. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 125-134 28740344-9 2017 In vitro, rosuvastatin significantly reduced the production of ROS, inflammatory mediators and apoptotic markers in TNF-alpha-treated IEC-6 cells (P < 0.05). Rosuvastatin Calcium 10-22 tumor necrosis factor Rattus norvegicus 116-125 35130744-0 2022 Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-alpha expressions affecting oxidative/nitrosative stress and inflammation. Rosuvastatin Calcium 21-33 tumor necrosis factor Rattus norvegicus 120-129 33641435-8 2021 Administration of rosuvastatin reduced the increases in expression of NLRP3, ASC, pro-caspase-1, TLR4, and p65 and decreased the contents of TNF-alpha, IL-1beta, IL-18 and IL-6, with a similar effect as MCC950 (NLRP3 inhibitor). Rosuvastatin Calcium 18-30 tumor necrosis factor Rattus norvegicus 141-150 30519383-11 2018 Rosuvastatin use also resulted in reduction of TNF-alpha, IL-6, and MDA levels. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 47-56 15681303-6 2005 In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta. Rosuvastatin Calcium 42-54 tumor necrosis factor Rattus norvegicus 181-208 26633263-7 2016 Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1beta, TNF-alpha) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine. Rosuvastatin Calcium 10-22 tumor necrosis factor Rattus norvegicus 230-239 25821305-8 2015 Simvastatin or rosuvastatin counteracted the reduction in colon length, decreased colon weight, neutrophil accumulation, and tumor necrosis factor-alpha level in TNBS-induced colitis. Rosuvastatin Calcium 15-27 tumor necrosis factor Rattus norvegicus 125-152 24529602-8 2014 The increased expressions of tumor necrosis factor-alpha, endothelial matrix metalloproteinase-9, and neuronal cyclooxygenase-2 induced by SAH were prevented by rosuvastatin pretreatment. Rosuvastatin Calcium 161-173 tumor necrosis factor Rattus norvegicus 29-56 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 tumor necrosis factor Rattus norvegicus 175-202 22732653-6 2012 Treatment with rosuvastatin (5 or 10 mg/kg) for 8 weeks in myocardial-infarct rats enhanced the electrocardiographic pattern, reduced serum cardiac biomarkers, reduced tissue tumor necrosis factor-alpha (TNF-alpha) and upregulated vascular endothelial growth factor (VEGF) level. Rosuvastatin Calcium 15-27 tumor necrosis factor Rattus norvegicus 204-213 20588182-0 2010 Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Rosuvastatin Calcium 32-44 tumor necrosis factor Rattus norvegicus 96-123 20588182-7 2010 Moreover, treatment of rosuvastatin markedly improved ventricular remodeling and cardiac function in rats, which was associated with attenuations in both TNF-alpha gene expression and p38 MAP kinase activity in myocardium without changes in serum lipid levels. Rosuvastatin Calcium 23-35 tumor necrosis factor Rattus norvegicus 154-163 20588182-8 2010 CONCLUSIONS: Treatment of rosuvastatin was able to improve cardiac remodeling and cardiac function after acute MI, which was associated with attenuations in both expression of TNF-alpha and activity of p38 MAP kinase in myocardium. Rosuvastatin Calcium 26-38 tumor necrosis factor Rattus norvegicus 176-185 16610051-11 2006 Furthermore, mRNA expression of CINC-1 and TNF-alpha was increased after I-R, and this increase was also inhibited by rosuvastatin. Rosuvastatin Calcium 118-130 tumor necrosis factor Rattus norvegicus 43-52 25940601-12 2015 In addition, rosuvastatin treatment reduced intrapulmonary shunts and plasma levels of VEGF and TNF-alpha. Rosuvastatin Calcium 13-25 tumor necrosis factor Rattus norvegicus 96-105 25940601-14 2015 We concluded that rosuvastatin alleviates experimental HPS through blockade of pulmonary inflammatory angiogenesis via TNF-alpha/NF-kappaB and VEGF/Rho-associated A kinase pathways down-regulation. Rosuvastatin Calcium 18-30 tumor necrosis factor Rattus norvegicus 119-128 25445360-10 2015 Additionally, the activation of astrocytes, the phosphorylation of extracellular signal-regulated kinase 42/44 (ERK(42/44)) and the expressions of TNFalpha and IL-1beta were inhibited significantly by rosuvastatin. Rosuvastatin Calcium 201-213 tumor necrosis factor Rattus norvegicus 147-155 22916066-0 2012 Rosuvastatin inhibits the smooth muscle cell proliferation by targeting TNFalpha mediated Rho kinase pathway. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 72-80 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 198-210 tumor necrosis factor Rattus norvegicus 34-61 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 198-210 tumor necrosis factor Rattus norvegicus 63-71 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 289-301 tumor necrosis factor Rattus norvegicus 34-61 22916066-1 2012 OBJECTIVE: To investigate whether Tumor Necrosis Factor-alpha (TNFalpha) is capable of activating Rho kinase pathway which leads to smooth muscle cell proliferation and the intervention function of Rosuvastatin, and clarify the mechanism and intervention manner of anti-atherosclerosis by Rosuvastatin. Rosuvastatin Calcium 289-301 tumor necrosis factor Rattus norvegicus 63-71 22212364-8 2012 Ros attenuated tubular dilatation (33%) and interstitial fibrosis (72%) in association with the normalization of renal TGF-beta(1) and TNF-alpha mRNA levels. Rosuvastatin Calcium 0-3 tumor necrosis factor Rattus norvegicus 135-144 20121625-6 2010 Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-alpha, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production. Rosuvastatin Calcium 0-12 tumor necrosis factor Rattus norvegicus 135-144 19948880-12 2010 The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. Rosuvastatin Calcium 132-144 tumor necrosis factor Rattus norvegicus 32-41